Importantly, in endocrine therapy-resistant breast cancer cells, the regulation of KDM4B by HIF-1α and ERα is intact and KDM4B is still required for G2/M phase progression [59] (Figure 2B). This evidence concerns the gene ESR1 and breast carcinoma.